RxDoctor Payments Data

Warren Line, MD

Plastic Surgery within the Head & Neck · Burbank, CANPI 1205918588

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.7% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $814 and has fallen 73.7% since, to $214 in 2024.

$3,041in general payments, 2019–2025

Across 122 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$677
  • Optinose US, Inc.$511
  • Regeneron Healthcare Solutions, Inc.$487
  • GSK$275
  • Novartis$193
  • Acclarent, Inc$177
  • plus $721 from 10 others

What the payments were for

  • Food & beverage$2,94197%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,041 in reported general payments places this provider in the 75th percentile of 119 plastic surgery within the head & neck providers in California.

See all plastic surgery within the head & neck providers in California

Medicare billing

Part B allowed, 2024
$244,630
Medicare patients
1,210
Services billed
8,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab18$97,469
Ipratropium Bromide336$10,070
Azelastine Hcl133$5,101
Mometasone Furoate50$3,804
Fluticasone Propionate213$2,752
Montelukast Sodium362$2,324
Azelastine-FluticasoneAzelastine/Fluticasone21$2,155
CeftriaxoneCeftriaxone Sodium26$2,139
Famotidine150$1,660
Pilocarpine Hcl23$1,302
Omeprazole80$1,211
Doxycycline Monohydrate48$1,025
Cefdinir50$885
Triamcinolone Acetonide16$853
Glycopyrrolate31$833

Paid to pharmacies, not to this prescriber.

Other plastic surgery within the head & neck in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →